Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. specializes in developing and manufacturing implantable medical devices for the treatment of sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand. However, the company failed to adequately prepare clinicians and payors, leading to significant delays in adoption [6][7]. - The launch of Inspire V faced an "elongated timeframe," resulting in a reduction of the 2025 earnings per share guidance by over 80%. Contributing factors included incomplete training at implanting centers and poor demand due to excess inventory of older devices [8]. Stock Performance - Following the announcement of the delays, Inspire's stock price plummeted by $42.04 per share, a decrease of more than 32%, dropping from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [9].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged securities fraud affecting shareholders between August 6, 2024, and August 4, 2025 [2] Group 1: Lawsuit Details - The lawsuit claims that the company made false statements and concealed the poor demand for its new product, Inspire V, which was launched unsuccessfully due to significant surplus inventory and reluctance from providers to adopt the new treatment [3] - The complaint highlights that the company failed to complete essential tasks for a successful launch, including training and onboarding for treatment center customers, setting up IT systems, updating insurer claims software, and ensuring Medicare reimbursement was in place [3] Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4] Group 3: Legal Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States [5]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit claims are based on Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in Inspire stock. The case is currently pending in the U.S. District Court for the District of Minnesota [3]. Stock Performance - On August 4, 2025, Inspire announced that the launch of Inspire V would face an "elongated timeframe," leading to a reduction in its 2025 earnings per share guidance by over 80%. This announcement was attributed to undisclosed factors affecting the rollout and weak demand due to excess inventory of older devices [7][8]. Impact of News - Following the announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [2][4]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 5, 2026 [4][6]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [5]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's new Inspire V device and its market demand [2][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Inspire Medical to contact them directly to discuss their legal options [1]. - There is a deadline of January 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Inspire Medical [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [8]. Group 2: Company Performance and Issues - Inspire Medical announced significant setbacks in the launch of its Inspire V device, citing delays due to incomplete training and onboarding at treatment centers [6]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not effective until July 1, 2025, leading to continued use of the older Inspire IV system [6]. - Inspire reported weak demand and excess inventory for the Inspire V, resulting in a more than 80% cut in its 2025 earnings guidance [7]. Group 3: Market Impact - Following the announcement of these issues, Inspire Medical's stock price dropped over 32% in one day, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [7].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 5, 2026, to request to lead the case in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors of a timely launch for Inspire V, but failed to prepare clinicians and payors adequately, leading to delays and weak demand due to excess inventory of older devices [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04, or more than 32%, from $129.95 to $87.91 per share [8].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand [5][6]. - The company disclosed on August 4, 2025, that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. Stock Performance - Following the announcement of the delayed launch, Inspire's stock price fell by $42.04 per share, a decline of more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Rosen Law Firm is reminding investors of Inspire Medical Systems, Inc. to secure counsel before the January 5, 2026 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 5, 2026 [3][5]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged securities fraud affecting shareholders between August 6, 2024, and August 4, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that the company made false statements regarding the launch of its new product, Inspire V, which was reportedly unsuccessful due to poor demand and excess inventory at treatment centers [3]. - Allegations include that Inspire Medical Systems failed to complete essential tasks for a successful product launch, such as training for treatment center customers, setting up IT systems, and ensuring proper Medicare reimbursement [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who experienced losses during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].